Exosomes and Cardiovascular Protection by Davidson, SM et al.
1 23
Cardiovascular Drugs and Therapy
 
ISSN 0920-3206
Volume 31
Number 1
 
Cardiovasc Drugs Ther (2017) 31:77-86
DOI 10.1007/s10557-016-6698-6
Exosomes and Cardiovascular Protection
Sean M. Davidson, Kaloyan Takov &
Derek M. Yellon
1 23
Your article is published under the Creative
Commons Attribution license which allows
users to read, copy, distribute and make
derivative works, as long as the author of
the original work is cited. You may self-
archive this article on your own website, an
institutional repository or funder’s repository
and make it publicly available immediately.
ORIGINAL ARTICLE
Exosomes and Cardiovascular Protection
Sean M. Davidson1 & Kaloyan Takov1 & Derek M. Yellon1
Published online: 29 October 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Most, if not all, cells of the cardiovascular system
secrete small, lipid bilayer vesicles called exosomes. Despite
technical challenges in their purification and analysis, exosomes
from various sources have been shown to be powerfully
cardioprotective. Indeed, it is possible that much of the so-
called Bparacrine^ benefit in cardiovascular function obtained
by stem cell therapy can be replicated by the injection of
exosomes produced by stem cells. However, exosomes purified
from plasma appear to be just as capable of activating
cardioprotective pathways. We discuss the potential roles of
endogenous exosomes in the cardiovascular system, how this
is perturbed in cardiovascular disease, and evaluate their poten-
tial as therapeutic agents to protect the heart.
Keywords Exosomes .Microvesicles .Microparticles . Stem
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Introduction
What Are Exosomes?
The term Bexosome^ was first used to describe sub-micron
sized lipid vesicles released from cells, in 1981 [1].
Subsequently, the term was used more specifically to refer to
~50 nm diameter vesicles containing transferrin receptors re-
leased from maturing blood reticulocytes (Fig. 1a) [2, 3]. For
many years afterwards, exosomes were considered to be purely
a means for the cell to shed excess proteins. However, the dem-
onstration in 2007 that they contained miRNA that could be
transferred between cells [4], stimulated great interest in their
potential as both biomarkers, and as therapeutic agents.
Most, if not all, types of cell release exosomes of 50–
150 nm diameter. These are produced initially by intraluminal
vesiculation within endosomal multivesicular bodies, and are
referred to as exosomes when they are released from the cell.
As such, they differ from microvesicles which are released by
shedding of plasma membrane and are typically 100 nm -
1 μm in diameter. However, most currently used techniques
are unable to obtain completely pure exosomes, and provide a
mixture of exosomes, microvesicles and other extracellular
vesicles such as apoptotic bodies [5, 6]. It has therefore been
suggested that experimentally used isolates of cellular vesicles
should be referred to conservatively as Bextracellular vesicles^
(EVs) or small EVs (sEVs) [5].
Commonly used techniques to isolate sEVs from blood or
tissue culture medium include ultracentrifugation, precipita-
tion, affinity-isolation and size-exclusion chromatography
[7]. However, as mentioned, none of these methods are perfect
and lead to co-isolation of sEVs containing some degree of
microvesicles [5, 6]. Density gradient purification may be
used to increase the purification of lighter vesicles from more
dense proteins, but is time-consuming and low throughput.
Furthermore, since other blood components such as lipopro-
teins, protein macromolecular complexes and plasma proteins
can be of a similar size and even similar density to exosomes
theywill still contaminate the isolated vesicles to some degree.
Similarly, when isolating sEVs from cultured cells, it is im-
portant to use serum-free medium or culture cells with serum
that has been pre-cleared of sEVs, in order to reduce contam-
ination by EVs and other serum components. Exosome-free
serum is available commercially or can be prepared by over-
night ultracentrifugation [8]. When using serum-free medium,
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an important additional consideration is the health of the cells,
since cells undergoing apoptosis will fragment, releasing ap-
optotic bodies that can contaminate the purified vesicles.
Given the steps that must be taken in order to achieve sEV
populations of reasonable purity, it is challenging to obtain
yields of vesicles sufficient for downstream biochemical ex-
periments. It can be calculated that, theoretically, a single
exosome of 100 nm diameter contains ~1500 proteins
(Table 1). Therefore, in a completely pure preparation of all
~1010 plasma exosomes in 1 ml of blood [9, 10], the maxi-
mum yield is expected to be just ~1 μg protein. Exosome
concentration in conditioned, tissue-culture medium is typi-
cally much lower, meaning that litres of medium may be re-
quired to obtain sufficient protein for analysis. In terms of
miRNA, Chevillet et al. determined that on average, there
was far less than one molecule of a given miRNA per
exosome, and that on average, over 100 exosomes would need
to be examined to observe one copy of a given abundant
miRNA [11]. On the other hand, PCR-based techniques greatly
increase the sensitivity of miRNA or mRNA analysis.
Proteins from the Endosomal Sorting Complexes
Required for Transport (ESCRT) machinery are involved
in exosome release and commonly found associated with
exosomes. However, since inhibition of key ESCRT pro-
teins does not completely eliminate exosome production,
ESCRT-independent mechanisms are also believed to be
involved [12] (reviewed in [13]). Since ceramide is
enriched in exosomes and was proposed to be involved
in their intraluminal formation, neutral sphingomyelinase
inhibitors have been used to inhibit exosome production
[12]. However care must be taken in interpreting experi-
ments, since these inhibitors are unlikely to be specific for
exosome release [13].
The use of flow cytometry is challenging, even for the
detection of microvesicles [14]. Since they are smaller even
than the wave-length of light, specialized techniques have
been developed to quantify and visualize exosomes. In partic-
ular due to their small size, flow cytometry is not applicable,
and techniques such as nanoparticle tracking analysis
(Fig. 1e), dynamic light scattering, or atomic forcemicroscopy
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Fig. 1 a Fusion of multivesicular endosomes with the plasma membrane
of sheep reticulocytes and their release by exocytosis as exosomes. The
gold-labelled antibodies against transferrin receptors bind to 50-nm
vesicles which are inside openings of 300–800 nm in diameter.
Reprinted with permission from Pan et al. [3]. b, c Cryo-electron
microscopy of EVs from pure plasma. Spherical EVs embedded in a thin
film of frozen platelet-free plasma. EV diameters are 185 nm in (b) and
45 nm and 60 nm in (c). The lipid bilayer at the periphery of EVs is
resolved in two dark lines 4 nm apart (arrow in b). The granular aspect
of the background is due to the high protein content of plasma. Scale bars:
100 nm. Reprinted with permission from [14]. d Transmission electron
microscopy of exosome enriched from rat plasma by differential
ultracentrifugation. Scale bar: 100 nm. e Size distribution exosome
produced by primary adult rat cardiomyocytes as determined by
nanoparticle tracking analysis
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must be used to ascertain their size-range and concentration
[7]. Transmission electron micrography or cryo-electron mi-
croscopy is useful to demonstrate the vesicular nature of the
particles (Fig. 1b-d) [15]. Exosomes-associated proteins such
as those involved in the ESCRT machinery, tetraspanins (e.g.:
CD9, CD63, CD81), and HSP70 are commonly used as pro-
tein markers to further verify sEV identity as exosomes, al-
though recent evidence suggests that some of these markers
are not as specific for exosomes as once thought [5]. MVs can
be further characterized by their expression of surface mem-
brane markers which reflect their cell type of origin. It is
important to note that, due to their endosomal origin, many
exosomes do express similar membrane markers, and it can be
more difficult to identify their cell type of origin [14].
However, as the contents of EVs typically reflect the contents
of the cell of origin, profiling of the EV constituents can po-
tentially be informative in the identification of biomarkers.
What Are the Roles of Microvesicles and Exosomes
from Cells of the Cardiovascular System?
Both microvesicles and exosomes may have roles in diabetes,
cardiovascular disease, endothelial dysfunction, coagulopa-
thies, and polycystic ovary syndrome [7]. For example, ele-
vated levels of circulating microvesicles of endothelial origin
and with procoagulant potential are found in the blood of
patients with acute coronary syndromes [16]. Measuring
endothelial microvesicles as an indicator of endothelial
dysfunction can help to identify patients vulnerable to coronary
heart disease [17].
The blood of healthy individuals contains enormous num-
bers of sEVs, estimated to be on the order of 1010 vesicles per
ml of plasma [9, 10]. These are believed to originate mainly
from platelets and erythrocytes, but lymphocytes, endothelial
cells and parenchymal cells also contribute. Arraud et al. used
a method of cryo-electron microscopy which preserves the
structure of EVs in solution and demonstrated that EVs are
primarily spherical with a diameter ~ 200 nm, although they
also observed larger, tubular structures of unknown origin
(Fig. 1b,c) [14]. By sedimenting and quantifying vesicles onto
electron microscope grids, they arrived at a conservative
estimate of 5 × 107 / ml sEVs in platelet-free plasma. By
examining the expression of surface marker proteins they
concluded that similar numbers of vesicles were derived
from platelets and erythrocytes [14]. Given the high numbers
of sEVs in the plasma of healthy individuals, it is important to
determine whether they have functions other than simply
waste disposal. Evidence from the literature supporting the
role of EVs of different origin in cardiovascular disease is
summarized in Table 2 and will be discussed further below.
The role of platelet sEVs is unclear as they appear to have
both detrimental and beneficial effects [18]. They are often
pro-thrombotic, but platelet-derived sEVs can also stimulate
angiogenesis both in vitro and in vivo [19, 20]. Injection
of platelet microvesicles into the ischaemic myocardium
increased the number of functioning capillaries in a rat
model of chronic myocardial ischaemia [20]. After vascular
injury, platelets become activated locally, and degranulate,
releasing sEVs including both exosomes and microvesicles
[21]. Platelet-derived sEVs have been shown to interact
with angiogenic early outgrowth cells, altering SDF-1α/
CXCR4 signalling, and stimulating their maturation and
re-endothelialisation [22]. Irrespective of their function,
measurement of plasma microvesicle concentration may
have a useful diagnostic role. For example, in the absence
of coronary artery disease, the numbers of microvesicles
derived from platelets and other cell types increased im-
mediately following a stress echocardiogram, while in the
presence of coronary artery disease numbers remained un-
changed [23].
Cardiomyocytes have been shown to release exosomes, at
least in vitro (Fig. 1e) [24, 25]. The protein and mRNA con-
tent of their exosomes varies under different culture conditions
and stimulus such as oxidative stress [24, 26]. Under condi-
tions of oxidative stress or glucose deprivation, neonatal
cardiomyocytes and cardiac-like H9c2 cells release increased
numbers of exosomes [27]. In co-culture with endothelial
cells, these exosomes induced endothelial proliferation and
Table 1 Calculation of the
number of proteins per a typical
exosome and cell
Spherical exosome Cube-shaped cell
Diameter / length 100 nm 15 μm
Volume 0.0005 μm3 3375 μm3
Density 1.15 g/ml 1.03 g/ml
Mass (volume x density) 6.0 × 10−7 ng 3.48 ng
Mass of protein (20 % of totala) 1.2 × 10−7 ng 0.70 ng
Number of proteinsa,b 1390 8.0 × 109
Number of exosomes/cells required for 1 μg of protein 8.3 × 109 1430
aAssumptions made are that protein accounts for 20 % of the total exosome mass and that the average protein
mass is 52 kDa, as has been determined to be the case for eukaryotic cells [60]
b Number of proteins = mass of proteins / 52,000 x Avogadro’s constant
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Table 2 Roles of EVs released from the cells of the cardiovascular system
Cell/organ of the
vesicular origin
Source Type of EVs Cargo mediator Function References
A: Roles of EVs originating from different cells of the cardiovascular system
Endothelial cells HUVECs, mouse
H5V cell line
Microvesicles,
exosomes
miRNA-143, miRNA-
145
Endothelial cells subjected to shear
stress or overexpressing Krüppel-
like Factor 2 (activated by shear
stress) have increased expression
of miRNA-143 and miRNA-145
which are secreted in the extracel-
lular vesicle fraction and trans-
ferred to smooth muscle cells. This
was atheroprotective in a mouse
model. Procedure for microvesicle
isolation followed, although au-
thors noted that majority of vesi-
cles are reminiscent of exosomes.
[37]
Endothelial cells Human microvascular
endothelial cell line
Exosomes miRNA-214 Increased migration and tube
formation of recipient endothelial
cells abolished by depletion of
miRNA-214 by antagomir. In mice
in vivo angiogenesis was increased
in implanted matrigel plugs loaded
with endothelial cell-derived
exosomes but not in plugs loaded
with exosomes isolated from
antagomir-treated endothelial cells.
[38]
Cardiomyocytes HL-1 cell line Exosomes Not determined Growth factor (TGF-β2, PDGF-BB)
treatment affected messenger
RNA contents of exosomes
secreted by cardiomyocytes. No
function reported.
[26]
Cardiomyocytes Rat (neonatal) Exosomes GLUT1, GLUT4 Glucose deprivation of neonatal rat
cardiomyocytes increased
production of exosomes carrying
GLUT1 and GLUT4 transporters
which were transferred to rat
cardiac microvascular endothelial
cells to stimulate uptake of glucose
and glycolysis.
[27]
Cardiomyocytes H9C2 cell line Exosomes Not determined Glucose deprivation increases
production of exosomes in
cardiomyocytes which can be
transferred to HUVECs and induce
transcriptional changes,
proliferation and tube formation
in vitro. Differential protein and
miRNA content demonstrated
under normal conditions or
glucose deprivation which may
account for these effects.
[28]
Platelets Human Microparticles Lipid growth factors Increased survival, proliferation and
migration of HUVECs reduced by
treatment with activated charcoal
suggesting involvement of lipid
growth factor mediators.
[19]
Platelets Human Microparticles VEGF, bFGF, PDGF,
heparanase
Stimulation of sprouting
angiogenesis in a rat aortic ring
model. Increased migration of
endothelial cells through a
matrigel membrane. Induction of
angiogenesis in vivo in implanted
[20]
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Table 2 (continued)
Cell/organ of the
vesicular origin
Source Type of EVs Cargo mediator Function References
agarose beads containing platelet
microparticles. Induction of
revascularisation after chronic
myocardial infarction in rats.
Platelets Human Microparticles CXCR4 Increased expression of mature
endothelial cell markers, adhesion
and migration of angiogenic early
outgrowth cells by increase in
CXCR4. Reduction of neointima
formation after wire injury in mice
in vivo.
[22]
Blood plasma/unknown
cell type
Rat, human Exosomes HSP70 Protection against myocardial
ischaemia-reperfusion injury
in vitro (isolated cardiomyocytes),
ex vivo (Langendorff heart prepa-
ration) and in vivo in rats by
HSP70/TLR-4-mediated activa-
tion of ERK/p38 pathway in
cardiomyocytes.
[10]
Reticulocytes Rat [2], sheep [3] Exosomes Transferring receptors Disposal of transferrin receptors
needed for maturation of
reticulocytes.
[2, 3]
B: EVs and cardiovascular disease
Blood plasma, lungs Mice (pulmonary
arterial hypertension)
Exosomes Differential miRNA
profile in healthy and
diseased animals
Exosomes isolated from blood
plasma or lungs of mice with
pulmonary arterial hypertension
induce right ventricular
hypertrophy and remodelling of
the pulmonary vasculature in
recipient healthy mice.
[41]
Blood plasma,
endothelial
progenitor cells
Human Microvesicles miRNA-126/VEGFR2 Reduction of endothelial progenitor
cell migration, increased apoptosis
and increased production of ROS
upon treatment with blood plasma-
derived or endothelial progenitor
cell-derived microvesicles from
patients with uncontrolled diabetes.
Microvesicles from healthy con-
trols had opposite effects. Effects
attributed to decreased levels of
miRNA-126 and VEGFR2 in en-
dothelial progenitor cells in un-
controlled diabetes.
[30]
Blood plasma
(endothelial origin)
Human Microparticles N/A Endothelial microparticles with
procoagulant potential were
elevated in patients with unstable
angina and myocardial infarction.
No function reported.
[16]
Platelets, erythrocytes,
endothelial cells
Human Microparticles N/A Rise in platelet, erythrocyte and
endothelial cell microparticles
with procoagulant potential after
sympathomimetic stress
echocardiogram in healthy but not
vascular disease patients. No
function identified.
[23]
Pericytes, endothelial
cells
Human Exosomes Not determined Pericytes stimulated with CoCl2
induce pro-angiogenic response in
endothelial cell as shown in would
healing and spinal cord tissue an-
giogenesis assays. These pro-
[36]
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angiogenesis as well as increasing glucose uptake and gly-
colytic activity in recipient cells [27, 28]. Interestingly,
exosomes obtained from diabetic rat myocytes have not
only lost their pro-angiogenic capacity, but actively inhibit
angiogenesis [29]. This appears to be via exosomal trans-
fer of miR-320 and down-regulation of its target genes
(IGF-1, Hsp20 and Ets2) in recipient cardiac endothelial
cells [29]. Circulating microvesicles of diabetic mice have
also been found to have negative effects on the function
of endothelial progenitor cells due to altered miR-126
levels [30]. Thus, a loss of exosomal function may contribute
to some aspects of cardiovascular diseases.
Vascular calcification is associated with major adverse
cardiovascular events. In the earliest phase of mineraliza-
tion, vascular smooth muscle cells secrete exosomes which
nucleate calcium phosphate crystals and promote vascular
calcification [31]. This response is exacerbated in response
to environmental calcium stress, suggesting that modula-
tion of the exosome release pathway in vascular smooth
muscle cells may be a novel therapeutic target for prevention
of calcification.
There is increasing interest in the mechanisms of com-
munication between cell types of the heart, and whether
these can be harnessed for therapeutic purposes. For exam-
ple, some drugs may work by stimulating communication
of cardioprotective pathways between endothelium and
cardiomyocytes [32]. Exosomes and microvesicles are an
important means of intercellular communication, particularly
during development and via specialized channels of commu-
nication such as the immune synapse [33, 34], but evidence is
accumulating for their communication role in the cardiovas-
cular system [7, 35]. For example, co-culture of primary en-
dothelial cells with activated pericytes, which normally sur-
round and communicate with them in vivo, stimulates their
angiogenic properties in an exosome-dependent manner [36].
Endothelial cells control target gene expression in co-cultured
smooth muscle cells by transferring sEVs enriched in miR-
143/145 in response to shear stress [37]. The therapeutic po-
tential of this novel pathway was demonstrated by injecting
sEVs into atherosclerosis-prone ApoE(−/−) mice and observ-
ing a reduction in atherosclerotic lesion formation in the aorta
[37]. A further benefit of endothelial cell-derived exosomes is
that they stimulate migration and angiogenesis in recipient
cells [7]. This effect was found to be dependent on expression
of miR-214 [38]. Data such as this has increased interest in the
potential for the use of sEVs and exosomes as therapeutic
agents.
What Is the Therapeutic Potential of Exosomes?
Exosomes have been found to offer therapeutic benefit in var-
ious experimental cardiovascular models (Table 3). For exam-
ple, sEVs derived from adiposemesenchymal stem cells (MSC)
inhibit vascular smooth muscle proliferation and migration
Table 2 (continued)
Cell/organ of the
vesicular origin
Source Type of EVs Cargo mediator Function References
angiogenic effects were ameliorat-
ed upon pharmacological inhibi-
tion of exosome secretion.
Vascular smooth
muscle cells
Human Exosomes / matrix
vesicles
Calcium/phosphate
deposits
Vascular smooth muscle cell-derived
matrix vesicles (identified as
exosomes) shown to carry mineral
deposits. Calcifying conditions in-
creased exosome production of
vascular smooth muscle cells.
Chronic kidney disease and ath-
erosclerotic patients shown to have
high calcifying exosome content in
arteries.
[31]
Cardiomyocytes
Healthy and Goto-
Kakizaki diabetic
rats
Exosomes miRNA-320 Inhibition of proliferation and
migration of mouse cardiac
endothelial cells upon incubation
with exosomes secreted by Goto-
Kakizaki (GK) rat
cardiomyocytes. Exosomes isolat-
ed from healthy Wistar rats had
opposite effects. miRNA-320 was
upregulated in GK rats exosomes
and delivered to endothelial cells
inhibiting proangiogenic target
genes.
[29]
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in vitro, and when injected into mice over a 20 day period they
reduced the extent of intimal hyperplasia in transplanted vein
grafts [39]. Levels of inflammatory cytokines interleukin (IL)-6
and monocyte chemoattractant protein-1 (MCP-1) were also
reduced. Intravenous delivery of MSC-derived exosomes
also inhibited vascular remodelling and hypertension in a
mouse model of hypoxia-induced pulmonary hypertension,
potentially via inhibition of STAT3 signalling in pulmonary
artery endothelial cells [40]. Another interesting study pub-
lished very recently confirmed the potential of MSC-derived
exosomes in reversing pulmonary hypertension in mice, and
furthermore showed that exosomes derived from mice with
monocrotaline-induced pulmonary hypertension can induce
pulmonary hypertension when injected in a non-diseased
animal [41]. The differential effects were attributed to the differ-
ent miRNA profiles of the exosomes.
Injection of stem cells into the myocardium is able to pro-
tect the heart against ischaemia and reperfusion injury as well
as improving cardiac function after injury, via repair and pos-
sibly regeneration. Transplantation of human CD34+ve hema-
topoietic stem cells to ischemic tissues induces neovasculari-
zation in preclinical models and has been associated with re-
duced angina and improved exercise time in phase 2 clinical
trials. However, the benefits obtained in such experiments
frequently appear to depend more on paracrine signalling ef-
fects rather than on myocardial cell engraftment of the stem
cells [42]. sEVs, and exosomes in particular, have been hy-
pothesized to mediate some of this paracrine benefit [43].
Indeed, CD34+ve-secreted exosomes have angiogenic activity
both in vitro and in vivo [44]. Interestingly, despite the benefit
of CD34+ve exosomes observed on angiogenesis, CD34+ve
hematopoietic stem cells were not cardioprotective when
administered after acute myocardial infarction unless
engineered to express sonic hedgehog (Shh) [45].
The injection of exosomes derived from embryonic stem
cells into infarcted mouse hearts enhanced neovascularization,
cardiomyocyte survival, and reduced fibrosis, which was
linked to the delivery of miR-294 to c-kit+ve cardiac progeni-
tor cells in the myocardium and consequent increase in their
regenerative activity [46]. A further benefit of exosomes in
this example, is the lack of carcinogenic potential that they
represent in comparison to embryonic stem cells.
Exosomes from cardiac progenitor cells (CPCs) can be
obtained from atrial appendage explants from patients under-
going heart valve surgery [47]. When these exosomes were
administered to rats with myocardial infarction, there was less
cardiomyocyte apoptosis, enhanced angiogenesis, and
improved LV ejection fraction [47]. No matter which
type of stem cells is used, the majority of cells die or are lost
shortly after implantation. In order to improve their resistance
to hypoxia, CPCs were co-delivered with a non-viral,
minicircle plasmid carrying HIF1 (MC-HIF1) [48]. In vitro
experiments suggested that this caused endothelial cells to
overexpress HIF1, and produce exosomes with higher contents
of miR-126 and miR-210 that were actively internalized by
recipient CPCs, activating prosurvival kinases and inducing a
Table 3 Cardioprotection by cardiac-, plasma- and stem-cell-derived exosomes
Source of exosomes Protection observed Mechanism Reference
Cardiac endothelial cells Improved ejection fraction in mice after MI Delivery of miR-126 and miR-210 to CPCs,
activating prosurvival kinases and induc-
ing a glycolytic switch
[48]
Human or rat plasma Cardioprotection Exosomal HSP70 activating MAPK/ERK1/2
signalling via TLR4
[10]
CD34+ve haematopoietic stem cells Angiogenic activity both in vitro and in vivo Not determined [44]
Embryonic stem cells (ESCs) Enhanced neovascularization, cardiomyocyte
survival, and reduced fibrosis post MI
delivery of miR-294 to c-kit+ve cardiac pro-
genitor cells
[46]
Cardiac progenitor cells (CPCs) Stimulate the migration of endothelial cells
in vitro
Matrix metalloproteinases [49]
Cardiac progenitor cells (CPCs) Reduced apoptosis, enhanced angiogenesis,
improved ejection fraction in rat MI
Potentially via delivery of miR-210, miR-
132, and miR-146a-3p
[47]
Cardiospheres (CSp-EMVs) Primed fibroblasts, which stimulated
angiogenesis and cardioprotection when
injected in MI
Increased secretion of the SDF-1α and
VEGF
[52]
Cardiosphere-derived cells (CDCs) Improved cardiac function in murine MI
inhibiting apoptosis and promoting
proliferation of cardiomyocytes, while
enhancing angiogenesis
Potentially via delivery of miR-146a [50]
Cardiosphere-derived cells (CDCs) Decrease apoptosis and fibrosis and
improved function in a doxorubicin-
induced cardiomyopathy
Not determined [51]
Mesenchymal stem cells (MSCs) Reduced infarct size and improved recovery
in a mouse MI
Akt and GSK-3β signalling pathways [54–56]
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glycolytic switch [48]. Conversely, exosomes derived from
CPCs have also been shown to stimulate the migration of en-
dothelial cells [49].
Exosomes secreted by cardiosphere-derived cells (CDCs),
improved cardiac function when delivered in murine models
of myocardial infarction, inhibiting apoptosis and promoting
proliferation of cardiomyocytes, while enhancing angiogene-
sis [50]. Part of the benefit could be replicated by the admin-
istration of miR-146a, which was enriched in the exosomes
[50]. Furthermore, systemic delivery of these exosomes was
able to decrease apoptosis and fibrosis in a mouse model of
doxorubicin-induced dilated cardiomyopathy [51].
In a different approach, exosomes from cardiospheres
(CSp-EMVs), have been used to prime fibroblasts in vitro.
This exposure was found to increase fibroblast secretion of
the pro-angiogenic factors, stromal cell-derived factor 1 and
vascular endothelial growth factor [52, 53]. When injected
into the hearts of rats in a chronic model of myocardial infarc-
tion, the primed fibroblasts were found to stimulate significant
angiogenesis and cardioprotection [52].
Based on the above evidence that stem cell exosomes pro-
vide long-term benefit by stimulating cardioprotective path-
ways, experiments were performed to determine whether they
could confer cardioprotection acutely. Indeed, exosomes from
mesenchymal stem cells (MSCs) reduced infarct size and im-
proved recovery in a mouse model of myocardial ischemia/
reperfusion injury, via a mechanism that appeared to involve
Akt and GSK-3β [54–56]. Given the high number of
exosomes in blood, it was hypothesized that these may also
exert cardioprotective properties [7, 35, 57]. A population of
sEVs enriched in exosomes was purified from blood and
shown to protect rat hearts and cardiomyocytes against acute
ischaemia and reperfusion injury when administered either
in vivo or in vitro [10]. Protection was activated by HSP70
present in the exosomal membrane interacting with TLR4
receptor in cardiomyocytes, which lead to activation of the
MAPK/ERK1/2 signalling pathway [10]. It is not yet known
whether this process is perturbed under disease situations.
Some cardioprotective strategies have been shown to in-
crease the number of sEVs in the blood. For example, ischae-
mic preconditioning of an isolated, perfused rat heart increases
the release of HSP-60 containing vesicles [58]. Furthermore,
remote ischaemic preconditioning doubles the numbers of
exosomes in the blood [10] although this has not been associ-
ated with cardioprotective mechanism of remote ischaemic
conditioning [10].
Future Perspectives
Many questions remain in this new and exciting field of
exosome research. Not least are technological aspects of how
to obtain more pure populations of exosomes. Biologically, the
normal role of circulating exosomes is unclear. The ability to
study the in vivo role of exosomes will be greatly facilitated by
the discovery of a specific inhibitor of the production or up-
take. In terms of therapy, a better understanding of exosome
pharmacokinetics and pharmacodynamics is essential. Ideally,
a means of targeting them to the heart or target cells will be
required, in order to avoid the requirement for intramyocardial
delivery or the non-specific approach of systemic delivery.
Despite these hurdles, there remains great excitement about
the potential for exosomes as therapeutic agents in cardiovas-
cular diseases, and there are already blueprints in place for the
administration of extracellular vesicles based therapeutics in
clinical trials [59]. However, it is important that the excitement
for translation does not cloud the fact that there still remains a
great deal to learn about these tiny circulating vesicles.
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